NEIL JARIWALA: Open Payments
NPI 1710206545 · MAYWOOD, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,363 in 172 payments from 13 companies in 2025. Trend: 2023 $1,758 · 2024 $1,349 · 2025 $3,363
Food & beverage: $3,358Education: $5
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 23 | $559 |
| Neurocrine BioSciences, Inc. | 12 | $486 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $463 |
| Otsuka America Pharmaceutical, Inc. | 20 | $438 |
| Supernus Pharmaceuticals, Inc. | 21 | $372 |
| Janssen Pharmaceuticals, Inc | 12 | $285 |
| ABBVIE INC. | 22 | $168 |
| Vanda Pharmaceuticals Inc. | 11 | $154 |
| Lundbeck LLC | 8 | $145 |
| Tris Pharma Inc | 8 | $141 |
Products named: Auvelity, INGREZZA, REXULTI, CAPLYTA, Qelbree, SPRAVATO, VRAYLAR, FANAPT.
Industry payments across IL — which companies pay providers there.
